Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a pleomorphic illness originating from gene x environment interactions. Patients with differing symptom phenotypes receive the same diagnosis and similar treatment recommendations without regard to genomics, brain structure or function, or other physiologic or psychosocial factors. Using this present approach, only one third of patients enter remission with the first medication prescribed, and patients may take longer than 1 year to enter remission with repeated trials. Research to improve treatment effectiveness recently has focused on identification of intermediate phenotypes (IPs) that could parse the heterogeneous population of patients with MDD into subgroups with more homogeneous responses to treatment. Such IPs could be used to develop biomarkers that could be applied clinically to match patients with the treatment that would be most likely to lead to remission. Putative biomarkers include genetic polymorphisms, RNA and protein expression (transcriptome and proteome), neurotransmitter levels (metabolome), additional measures of signaling cascades, oscillatory synchrony, neuronal circuits and neural pathways (connectome), along with other possible physiologic measures. All of these measures represent components of a continuum that extends from proximity to the genome to proximity to the clinical phenotype of depression, and there are many levels along this continuum at which useful IPs may be defined. Because of the highly integrative nature of brain systems and the complex neurobiology of depression, the most useful biomarkers are likely to be those with intermediate proximity both to the genome and the clinical phenotype of MDD. Translation of findings across the spectrum from genotype to phenotype promises to better characterize the complex disruptions in signaling and neuroplasticity that accompany MDD, and ultimately to lead to greater understanding of the causes of depressive illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The origin of extracellular fields and currents — EEG, ECoG, LFP and spikes
Buzsáki, G., Anastassiou, C. A., & Koch, C. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3241 · Cited by 4,225
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · cited 1×
“7 the absence of a mechanism-based hypothesis for MDD, RDoC conceptualizes the illness as a disorder of brain circuits and reifies a framework in which cognitive and motivational domains (such as fear/extinction, reward, and executive function) are circuits will yield “biosignatures” that will…”
Intermediate phenotypes and genetic mechanisms of psychiatric disorders
Meyer-Lindenberg, A., & Weinberger, D. R. (2006) · Nature reviews. Neuroscience · doi:10.1038/nrn1993 · Cited by 1,216
A mega-analysis of genome-wide association studies for major depressive disorder
Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke, S., Wray, N. R., Lewis, C. M., Hamilton, S. P., Weissman, M. M., Breen, G., Byrne, E. M., Blackwood, D. H. R., Boomsma, D. I., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.21 · Cited by 1,120
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Kendler, K. S., Kuhn, J., & Prescott, C. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.631 · Cited by 799
The Genetics of Major Depression
Flint, J., & Kendler, K. S. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.027 · Cited by 724
Rhythmic and dysrhythmic thalamocortical dynamics: GABA systems and the edge effect
Llinás, R., Urbano, F. J., Leznik, E., Ramírez, R. R., & van Marle, H. J. F. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.04.006 · Cited by 549
Cited by
Oluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
“To date, pharmacogenetics/genomic biomarkers have yet to demonstrate a positive impact on health outcomes in clinical practice; however, future research may eventually prove biomarkers to be beneficial in selecting appropriate antidepressants in specific patient populations (Dunlop and Mayberg, 2014; Leuchter et al.,…”
BackgroundBrain arousal regulation as response predictor for antidepressant therapy in major depression
Schmidt, F. M., Sander, C., Dietz, M.-E., Nowak, C., Schröder, T., Mergl, R., Schönknecht, P., Himmerich, H., & Hegerl, U. (2017) · Scientific Reports · doi:10.1038/srep45187 · Cited by 61
MOUKADDAM, N., TRUONG, A., CAO, J., SHAH, A., & SABHARWAL, A. (2019) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000420 · Cited by 28
“11 The choice of questionnaires for assessment of depression was planned with the goal of including both a self-report measure (PHQ-9) and clinician-rated measures (HAM-A and HAM-D).”
Method
Metadata
- Authors
- Leuchter, A. F., Hunter, A. M., Krantz, D. E., & Cook, I. A.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2014-12-31
- Volume
- 16
- Issue
- 4
- Pages
- 525-537
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W1505291704
- Cited by
- 41
- References
- 21
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder. https://app.cochat.ai/papers/10.31887/dcns.2014.16.4/aleuchter
- The paper
- Leuchter, A. F., Hunter, A. M., Krantz, D. E., & Cook, I. A. (2014). Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2014.16.4/aleuchter
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.